

74
genes

CNVs,
SNVs, Indels

Find answers in your patient's blood

Targeted liquid biopsy for all advanced solid tumors to support your clinical decisions

TERT
promoter

Unusual
splicing

Gene
translocations



OncoSELECT™
by OncoDNA

WHY CHOOSE ONCOSELECT®?

OncoSELECT® helps optimize treatment strategies across all advanced solid tumors from just two tubes of blood, and matches patients with **targeted therapy**, **hormone therapy** and **potential clinical trials** to improve your patients' clinical outcomes. Rely on a blood-based biomarker-informed approach to make quick and personalized treatment plans for your patient.

IN WHAT SCENARIOS IS ONCOSELECT® USEFUL?

When your patients cannot have their tumor biopsied, when their tumor tissue sample is too old or too scarce for comprehensive biomarker testing, OncoSELECT® is the perfect alternative to support your clinical decisions thanks to a **fast** and **minimally invasive** analysis of circulating tumor DNA from a blood sample.

OncoSELECT® is available for **all advanced solid tumors in adults** and recommended for **stage 3 or 4** cancer patients when:

- Patient is receiving chemotherapy in neoadjuvant setting. OncoSELECT® may be used to inform on the **patient's response to treatment**.
- Patient is relapsing under current therapy. OncoSELECT® may be used after a line of treatment to **identify if the patient developed resistant mutations**.
- Patient is wild type for specific genes related to their cancer type based on the analysis of their solid biopsy. OncoSELECT® may be performed before the first line of treatment to **assess the heterogeneity of the disease**.

A 63-year-old man with stage IV prostate cancer (mCRPC), metastasized to lung, lymph node, bone

OncoSELECT allowed the identification of an **AR V890M** variant which explained the lack of clinical benefit of the previous hormonal therapies. Moreover, the detection of **BRCA2 somatic** and **ATM R3008C** variants led to the prescription of **olaparib** with a complete response, and no relapse was identified for the last 6 months.

A 55-year-old non-smoker male was diagnosed with metastatic non-small-cell lung carcinoma (NSCLC)

Oncologist requested to perform a liquid biopsy test since the lung needle biopsy obtained was of limited quantity. The patient was progressing under erlotinib and OncoSELECT allowed the detection of **EGFR T790M** variant. The detection of this variant led the oncologist to choose **osimertinib** which resulted in good response without any known relapse so far.

A 43-year-old woman with stage IV breast HR cancer, with recent relapse

OncoSELECT was performed because no solid biopsy was available for this patient. It allowed the identification of **ESR1 L536Q** and **PIK3CA E545K** mutations. Based on these biomarkers, it was decided to prescribe **alpelisib** in combination with **fulvestrant**, an FDA-approved treatment, to the patient. The patient responded well to the treatment without any relapse in the last 6 months.

Whole exons			Hotspots			Genes associated with translocatons		
ARID1A	CHEK2	NF1	AKT1	FOXL2	MAP2K1	ALK	FGFR2	NTRK2
ATM	FANCA	PALB2	ALK	GNA11	MYOD1	BRAF	FGFR3	NTRK3
ATR	FANCL	PTEN	AR	GNAQ	NTRK1	CD74	KIF5B	RET
BARD1	FGFR1	RAD51C	ARAF	GNAS	NTRK2	EGFR	KIT	ROS1
BRCA1	FGFR2	RAD51D	BRAF	H3F3A	NTRK3	EML4	MET	SDC4
BRCA2	FGFR3	RAD54L	CTNNB1	H3F3B	PDGFRA	ETV6	NPM1	SLC34A2
BRIP1	KEAP1	STK11	DICER1	H3C2	POLE	EZR	NRG1	
CDK12	MLH1		EGFR	IDH1	ROS1	FGFR1	NTRK1	
CDKN2A	MRE11A		ERBB4	IDH2	TERT			
CHEK1	NBN		ESR1	KIT				


Unusual splicing genes		
BRCA1	BRCA2	MET

OPTIMIZED PROCESS TO ACHIEVE **GREATER SENSIBILITY AND SPECIFICITY**

VAF= 0,25%
98,5 > % sensitivity
99,9 > % specificity
99,9 > % accuracy

ONCOSELECT® STEP BY STEP

Our teams are at hand to assist you every step of the way – from discussing the relevance of the test for your patient and easing the sample collection to understanding the clinical recommendations listed in the report.



ONCOSELECT[®] REPORT

The OncoSELECT report helps you **flag potential resistance mechanisms** and **optimize treatment strategies**.

Each report:

- Contains the patient's medical information (patient diagnosis, tumor type and stage, blood draw date ...)
- Reveals all actionable variants and their biological and therapeutical classifications according to ACMG/AMP guidelines
- Reveals a patient's receptiveness to targeted therapy or hormonal therapy
- Details all relevant recruiting clinical trials with detailed information on the drug development stage and its clinical benefit for your patient.

The screenshot displays the OncoSELECT report interface for a patient case. The top navigation bar includes 'OncoSHARE' and 'Workspace OncoSHARE'. The main content is divided into several sections:

- Medical Information:** Patient Case ID 20241126-1, Patient Name Hri, Sex Female, Country Armenia, Birthdate 1949/03/08, Cancer Breast cancer HR, Handler Prom-Test LLC, Medical doctor Diana Beglaryan.
- Drugs:** A table showing drug status: FDA approved (17 green, 9 red, 0 grey), Approved for other tumor types (0 green, 0 red, 0 grey), In development (0 green, 0 red, 0 grey).
- Comprehensive Summary:** Text stating: 'We did not find any pathogenic or likely pathogenic variants associated with treatments. No variant pathogenic nor likely pathogenic has been identified in PIK3CA (including E542 (K), E545 (A,D,G,K), H1047 (L,R,Y), Q546 (E,R)). Therefore we consider this variant as wild type. PIK3CA-inhibitors are associated with a lack of clinical benefit. No variant pathogenic nor likely pathogenic has been identified in ESR1. Therefore, we consider this variant as wild type.'
- Variants Detection:** A summary showing 0 Pathogenic, 1 Likely Pathogenic, and 8 Variants of Uncertain Significance (VUS).
- Other Biomarkers:** Fusion Panel (ctDNA) NO, MSI Stable.

The 'Variants Detection' section is expanded to show a detailed table of variants:

Gene	Category	Variant Frequency	Copy Number	cDNA Variant	Amino Acid Variant	Impact location	Biological impact	Therapeutical impact	Potenti
TP53	SNV	0.62%	0	NM_000546.6:c.475G>C	p.(A159P)	exon: 5	Likely Pathogenic	Tier III	No
BRCA1	WT	0	0	-	-	-	Wild type	Tier IA	No
ESR1	WT	0	0	-	-	-	Wild type	Tier IA	No
PIK3CA	WT	0	0	-	-	-	Wild type	Tier IA	No
BRCA2	SNV	2.74%	0	NM_000059.4:c.5474C>T	p.(A1825V)	exon: 11	Variant of Uncertain Significance (VUS)	Tier III	No
MET	SNV	55.37%	0	NM_000245.4:c.2584-1370C>T	-	intron: 11	Variant of Uncertain Significance (VUS)	Tier III	No

Contact us to discuss your patient case



OncoDNA-BioSequence

customersupport@oncodna.com +32 (0)71 18 35 00